Ali Erginay · enciclopedia

Publicaciones › Edema macular diabético y sus tratamientos

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6‐month results of a prospective controlled trial

Triamcinolona acetonida intravítrea para edema macular difuso diabético: resultados a 6 meses de un ensayo controlado prospectivo

Año2006
FuenteActa ophthalmologica Scandinavica
Tipoarticle · Journal Article, Randomized Controlled Trial
Autores (8)François Audren, Ali Erginay, Belkacem Haouchine, Rym Benosman, John Conrath, Jean-François Bergmann, Alain Gaudric, Pascale Massin
Posición de Erginay2 de 8
Citas118 (OpenAlex)
EnlacesDOI 10.1111/j.1600-0420.2006.00700.x · PubMed 16965492 · OpenAlex
LíneasEdema macular diabético y sus tratamientos Enfermedades vasculares, genéticas e inflamatorias de la retina Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo

En pocas palabras

Se estudió el efecto de una inyección intravítrea de triamcinolona acetonida en pacientes con edema macular difuso diabético que no respondían al tratamiento con láser. Los resultados mostraron una reducción significativa en el grosor macular y una mejora en la agudeza visual en la mayoría de los casos. Sin embargo, en algunos pacientes el edema macular volvió a aparecer después de 24 semanas.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

PURPOSE: To evaluate prospectively the efficacy and safety of one intravitreal injection of 4 mg triamcinolone acetonide for refractory diffuse diabetic macular edema. METHODS: Seventeen patients with bilateral diabetic macular edema unresponsive to laser photocoagulation. In all patients, one eye was injected, and the other served as a control. The intervention consisted in intravitreal injection of 4 mg triamcinolone acetonide. The main outcome measure was central macular thickness (CMT) at 4, 12 and 24 weeks, measured by Optical Coherence Tomography. Secondary outcomes were Early Treatment Diabetic Rentinopathy Study (ETDRS) scores, intraocular pressure and cataract PROGRESSION. RESULTS: Before injection, mean +/- SD CMT was 566.4 +/- 182.4 mum in injected eyes. Four, 12, and 24 weeks after injection, it was 228.4 +/- 47.5 mum, 210.9 +/- 87.2 mum and 358.5 +/- 160.5 mum respectively. CMT was significantly lower in injected eyes vs. control eyes except 24 weeks after injection because of a recurrence of macular edema in 9/17 injected eyes. Mean +/- SD gain in ETDRS score was significantly better in injected eyes vs. control eyes 4, 12 and 24 weeks after TA injection. In 9 of the 17 injected eyes, intraocular pressure exceeded 24 mmHg and was controlled by topical medication. CONCLUSION: In the short-term, intravitreal injection of triamcinolone effectively reduces macular thickening due to diffuse diabetic macular edema and improves visual acuity in most cases. The long-term effect of this treatment and predictive factors of visual recovery remain to be elucidated.

Términos MeSH

Adult Aged Diabetic Retinopathy Female Glucocorticoids Humans Injections Intraocular Pressure Macula Lutea Macular Edema Male Middle Aged Prospective Studies Tomography, Optical Coherence Treatment Outcome Triamcinolone Acetonide Visual Acuity Vitreous Body